The isozyme selective phosphodiesterase-4 inhibitor, ABI-4, attenuates the effects of lipopolysaccharide in human cells and rodent models of peripheral and CNS inflammation
Authors:
- 1 August 2017
- journal article
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 64, 285-295
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4Proceedings of the National Academy of Sciences, 2015
- Lipopolysaccharide-Induced Microglial Activation and Neuroprotection against Experimental Brain Injury Is Independent of Hematogenous TLR4The Journal of Neuroscience, 2012
- Neuroinflammation in Schizophrenia-Related Psychosis: A PET StudyJournal of Nuclear Medicine, 2009
- C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophreniaSchizophrenia Research, 2007
- In vivo detection of microglial activation in frontotemporal dementiaAnnals of Neurology, 2004
- PDE4 inhibition: a novel approach for the treatment of inflammatory bowel diseaseTrends in Pharmacological Sciences, 2004
- The two NF-κB activation pathways and their role in innate and adaptive immunityTrends in Immunology, 2004
- PET visualization of microglia in multiple sclerosis patients using [11C]PK11195European Journal of Neurology, 2003
- The Selective Phosphodiesterase 4 Inhibitor RP 73-401 Reduced Matrix Metalloproteinase 9 Activity and Transforming Growth Factor-β Release During Acute Lung Injury in Mice: The Role of the Balance Between Tumor Necrosis Factor-α and Interleukin-10The Journal of Pharmacology and Experimental Therapeutics, 2002
- Rolipram versus lmipramine in Inpatients with Major, ???Minor??? or Atypical Depressive Disorder: A Double-Blind Double-Dummy Study Aimed at Testing a Novel Therapeutic ApproachInternational Clinical Psychopharmacology, 1988